Patricia Inácio, PhD, science writer —

RestorGenex Pharmaceuticals, a biotechnology company developing innovative therapeutics for a large spectrum of diseases, including cancer and those of the dermatology and ophthalmology spectrum, recently presented at the American Thoracic Society International Conference in Denver, Colorado their latest results using RES-529 as a potential treatment for idiopathic pulmonary fibrosis.

iBio, Inc, a leading pharmaceutical company using plant-based technology for developing and manufacturing biological products, has announced that it is now collaborating with Caliber Biotherapeutics LLC, which will be responsible for scaling-up and producing the necessary equipment for clinical development of iBio, Inc.’s lead anti-fibrosis product, IBIO-CFB03.

In a new study entitled “Plasticity of Hopx+ type I alveolar cells to regenerate type II cells in the lung,” researchers report a new unrecognized capacity of adult lung cells, type I cells, to revert into another cell type (type II cells), spurring on lung regeneration…

In a new study entitled “Tryptase is involved in the development of early ventilator-induced pulmonary fibrosis in sepsis-induced lung injury,” researchers identified mechanical ventilation as an inducer of pulmonary fibrosis by modulating secretion of pro-fibrotic factors. The study was published in the journal Critical…

In a recent study entitled “Efficient Delivery to Human Lung Fibroblasts (WI-38) of Pirfenidone Incorporated into Liposomes Modified with Truncated Basic Fibroblast Growth Factor and Its Inhibitory Effect on Collagen Synthesis in Idiopathic Pulmonary Fibrosis,” researchers highlighted a promising, novel treatment for idiopathic pulmonary fibrosis that…

In a new study entitled “Telomere dysfunction causes alveolar stem cell failure,” a research team identified that short telomeres in lung stem cells induce stem cell failure, leading to the underlying cause of diseases like pulmonary fibrosis and emphysema. The study was published in the journal…

In a recent study entitled “Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis,” a team of researchers show acute exacerbations in idiopathic pulmonary fibrosis are caused by multifactorial cellular responses, including macrophage activation. The study was published in the open access journal…

A new study entitled “PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis” discovered mitochondria PINK1 impaired expression underlies the formation of fibrotic tissue in older patients lungs. The study was published in The Journal of Clinical Investigation. Idiopathic pulmonary fibrosis (IPF) is…

A new study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience” describes a prospective analysis performed in India to assess the burden of diffuse parenchymal lung diseases (DPLD), particularly two DPLD-causative disorders, idiopathic pulmonary…

In a new study entitled “Perivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis” a team of researchers identified a new key factor for the formation of fibrotic tissue. The study was published in the journal Cell Stem Cell. The findings could eventually lead to new…